Results will be out in 3 hours and the markets seem to be expecting bad news. The share price in London is down 3%. But will the results be bad - certainly not. Adderall XR and Vyvanse together will produce record sales figures - OK they have laid off some reps selling Fosrenol but that is small beer. The rest of the product sales should be good. So it all boils down to Vyvanse's market share - if that hasn't grown to at least 10% then the market will get worried. AXR's exclusivity ends in April 2009 and they have to get Vyvanse's market share up to 20% before then. They have 570 ADHD sales reps who are out there selling Vyvanse - AXR is not being promoted anymore. They have increased AXR's price so that Vyvanse's selling price is at a considerable discount to AXR's. If they can't get enough doctors to switch patients now then what will the position be when generic AXR's selling price drops like a stone? All will be revealed in the CC. Listen in.